CIPO Patents = 3

EPO Patents = 1

Forward Citations = 16

Loading Chart...

4 inventors (with patents filed for the assignee):

Matthew C Mulvey (5 out of 10 patents)

Ian J Mohr (4 out of 13 patents)

Steven R Fuhrmann (1 out of 7 patents)

4. Ram Aiyar (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 11147846 - Oncolytic herpes simplex virus and therapeutic uses thereof (2021-10-19),

2. 10456432 - Oncolytic herpes simplex virus and therapeutic uses thereof (2019-10-29),

3. 10232003 - Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof (2019-03-19),

4. 10105404 - Oncolytic herpes simplex virus and therapeutic uses thereof (2018-10-23),

5. 9623059 - Oncolytic herpes simplex virus and therapeutic uses thereof (2017-04-18),

Benevir Biopharm, Inc. is a biotechnology company focused on developing novel oncolytic viral therapies for cancer treatment. With a team of researchers and scientists dedicated to advancing the field of immuno-oncology, Benevir is at the forefront of innovative treatments that harness the power of the immune system to target and destroy cancer cells.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

5 Patents

#99 in Rockville, MD

#724 in Maryland

#50,165 in US

Rockville, MD, United States of America

Benevir Biopharm, Inc.

Forward Citations = 16

4 inventors:

Matthew C Mulvey (5 out of 10 patents)

Ian J Mohr (4 out of 13 patents)

Steven R Fuhrmann (1 out of 7 patents)

4. Ram Aiyar (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

3 patents (CIPO):

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com